Clinical trials
PD-1 Antibody clinical trials
Below are recruiting pd-1 antibody clinical trials, each written for real people, not researchers. We’re tracking 199 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06391190RecruitingPhase 1/Phase 2
Chemoradiation plus immunotherapy for advanced cervical cancer
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
ShanghaiAges 18–75 - NCT07416890RecruitingPhase 2
Study of thiotepa, pirtobrutinib, and sintilimab for CNS lymphoma
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
Hangzhou, ZhejiangAges 18–80 - NCT07518979RecruitingPhase 2
EGFR-targeted drug plus immunotherapy for advanced penile cancer
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
Chengdu, SichuanAges 18 years+ - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT04453826RecruitingPhase 3
Test PD-1 plus chemo-radiation for high-risk nasopharyngeal cancer
This Phase 3 trial tests whether adding a PD-1 immunotherapy (given with chemotherapy and radiation, and also after) can improve outcomes for people with high-risk nasopharyngeal cancer. It may help by strengthening the immune system’s attack on the cancer alongside standard treatment.
Guangzhou, GuangdongAges 18–70 - NCT04453813RecruitingPhase 3
Immunotherapy with chemoradiation for recurring nasopharyngeal cancer
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
Guangzhou, GuangdongAges 18–70 - NCT04778956RecruitingPhase 3
Toripalimab plus surgery vs surgery alone for recurring throat cancer
This trial tests whether adding toripalimab (an immune therapy) to surgery helps people with recurrent nasopharyngeal cancer live longer or control the cancer better than surgery alone. You may qualify if your recurrence can be fully removed by surgery and it came back after a certain amount of time.
Guangzhou, GuangdongAges 18–70 - NCT04785196RecruitingPhase 1/Phase 2
Testing an MDM2 drug plus an immune therapy for advanced tumors
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
Guangzhou, GuangdongAges 18 years+ - NCT05033392RecruitingPhase 2
PD-1 therapy plus chemotherapy before stomach cancer surgery
This Phase 2 trial tests whether adding a PD-1 antibody (JS001/toripalimab) to chemotherapy before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction adenocarcinoma. It aims to help shrink the tumor and make surgery more effective.
Shenzhen, GuangdongAges 18–79 - NCT05357846RecruitingPhase 3
Check whether PD-1 treatment helps esophagus cancer before surgery
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
Guangzhou, GuangdongAges 18–70 - NCT05394337RecruitingPhase 1/Phase 2
Immunotherapy before bladder surgery for cisplatin-ineligible patients
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
Houston, TexasAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Long Beach, CaliforniaAges 18 years+ - NCT05671510RecruitingPhase 3
Trial for metastatic lung cancer after PD-1 or PD-L1 treatment failure
This trial compares ONC-392 versus docetaxel (a standard chemotherapy) in metastatic squamous non-small cell lung cancer that has grown again after PD-1/PD-L1 immunotherapy. It’s testing whether ONC-392 can control the cancer better or more safely after prior treatment.
Dothan, AlabamaAges 18 years+ - NCT05795244RecruitingPhase 2
Nivolumab for resected mismatch-repair deficient endometrial cancer
This trial studies nivolumab (an immune therapy that helps your body recognize cancer) after surgery for endometrial cancer that has mismatch-repair deficiency (MMR-d) or high microsatellite instability (MSI-H). It aims to lower the chance the cancer comes back by treating “leftover risk” after the tumor is removed.
SeoulAges 20 years+ - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05980702RecruitingPhase 2
Comparing 2 vs 4 rounds of chemo-immunotherapy before surgery for head and neck cancer
This trial tests whether 2 or 4 cycles of pembrolizumab (immunotherapy) plus carboplatin and nab-paclitaxel (chemotherapy) before surgery works better for people with advanced head and neck cancer that can be removed. The goal is to see if fewer treatments are just as effective.
Guangzhou, GuangdongAges 18–75 - NCT06006650RecruitingPhase 2
Neoadjuvant therapy for stage II-IVA esophageal cancer
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06017583RecruitingPhase 3
Chemo plus immunotherapy and targeted radiation for advanced rectal cancer
This trial tests whether combining chemotherapy, immunotherapy (PD-1 inhibitor), and a precise type of radiation can help shrink locally advanced rectal cancer before surgery. It aims to improve treatment success and reduce side effects.
Nanning, GuangxiAges 18–70 - NCT06092957RecruitingPhase 3
Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06099821RecruitingPhase 2
KN046 plus targeted pills for resistant MSI-H digestive cancers
This trial tests two types of targeted therapy pills (Regorafenib or Apatinib) combined with a new immunotherapy drug (KN046). It is for people with MSI-H or dMMR digestive system cancers that have stopped responding to standard immunotherapy.
BeijingAges 18 years+ - NCT06313541RecruitingPhase 2
Adaptive radiation with immunotherapy for advanced lung cancer
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
ShanghaiAges 18 years+ - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06485271Recruiting
Camrelizumab for advanced gastric cancer
This trial tests a drug called camrelizumab, alone or with other treatments, for people with advanced stomach cancer that has worsened or returned. It aims to see how well this treatment works in real-world patients.
Changzhi, ShanxiAges 18–75
Hear when a new PD-1 Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pd-1 antibody?
- Yes. Clin2 currently lists 199 recruiting pd-1 antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pd-1 antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pd-1 antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.